Abstract:Objective: To investigate the effect of continuous veno-venous hemofiltration (CVVH) in the treatment of acute severe hyponatremia. Methods: Six patients with acute severe hyponatremia were studied, including 5 males and 1 female, aged 48.5 (25 - 61) years. Clinical manifestations of hyponatremia included confusion (6/6), drowsiness (3/6), and delirium (3/6). The course of hyponatremia before the initiation of CVVH was 45 - 48 hours. AN69, AV600, FH66 and HF1200 hemofilters were applied and changed every 24 hours. The ultrafiltration rate was 2 000 ml/h, with a blood flow rate of 200 - 250 ml/min, and the substitute fluid was infused by a pre-dilution route. Low molecular weight heparin was used for anticoagulation. Results: The average treatment duration of CVVH was 59.7 (45.6 - 86) hours. All the patients survived and tolerated CVVH well. During CVVH, the serum sodium increased significantly from (101.2 +/- 4.2) mmol/L before CVVH, to (115.0 +/- 2.7) mmol/L at the 6th hour of CVVH, (129.2 +/- 4.1) mmol/L at the 24th hour, and (140.3 +/- 1.6) mmol/L at the 48th hour of CVVH; with the correction rate of serum sodium controlled at (2.5 +/- 0.4) mmol.L(-1).h(-1) over the first 24 hours, (1.2 +/- 0.1) mmol.L(-1).h(-1) for the first 48th hour, and the correction rate of (0.82 +/- 0.10) mmol.L(-1).h(-1). The sodium concentrations in the replacement solution were (16.0 +/- 6.0) mmol/L higher than the serum sodium concentration at 0 hour, (11.6 +/- 4.3) mmol/L higher at 4th hour, (5.5 +/- 5.1) mmol/L higher at 24th hour, and (0.75 +/- 0.96) mmol/L higher at 48th hour of CVVH. After CVVH, the serum osmolarity increased significantly, from (216.7 +/- 7.4) mOsm/kgH(2)O pre-CVVH, to (245.0 +/- 5.5) mOsm/kgH(2)O at 6th hour, with a correction rate of (5.16 +/- 0.81) mOsm.kgH(2)O(-1).h(-1); (272.7 +/- 7.1) mOsm/kgH(2)O at 24th hour, with a correction rate of (2.33 +/- 0.28) mOsm.kgH(2)O(-1).h(-1); and (295.0 +/- 4.2) mOsm/kgH(2)O at 48th hour, with a correction rate of (1.63 +/- 0.20) mOsm.kgH(2)O(-1).h(-1). The Glasgow scores and APACHEII scores improved significantly as compared to pretreatment. Conclusion: CVVH is effective in the treatment of acute severe hyponatremia, and could be considered as a treatment option because of its slow and continuous nature. A low-sodium replacement solution should be prepared to minimize its sodium concentration difference from the serum concentration. We recommend that the serum sodium concentration be corrected at an average rate of (2.50 +/- 0.14) mmol.L(-1).h(-1) at 6 h, (1.2 +/- 0.1) mmol.L(-1).h(-1) at 24 h and (0.82 +/- 0.10) mmol.L(-1).h(-1) at 48 h.

Continuous Venovenous Hemofi Ltration with Citrate Based,calcium-,Mag Nesium-Free Replacement Solution in Acut E Renal Failure Patients at High Risk of Bleeding

Application of Continuous Veno-Venous Hemodiafiltration to Severely Acute Renal Failure after Cardiac Surgery

A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding

Regional Citrate Anticoagulation in Heparin-Contraindicative Critically Ill Patients During Continuous Venovenous Hemofiltration

Regional Citrate Plus Low Dose of Low Molecular Weight Heparins in Continuous Veno-Venous Hemofiltration

Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial

ACD-A Solution As Anticoagulant During Continuous Renal Replacement Therapy in High Risk Bleeding Patients

The effect of continuous renal replacement therapy in patients with acute kidney injury on the serum levels of urea,creatinine and cystatin C

[Continuous veno-venous haemofiltration in adult intensive therapy]

Changes of the Plasma Amino Acid Level in Patients with Abdominal Inflammation and Acute Renal Failure During Continuous Veno-Venous Hemofiltration

The Effect of Substitution Fluid Rate on the Prognosis of Critical Acute Kidney Injury Patients Treated with Continuous Veno-Venous Hemorfltration Therapy

Variables Associated with Circuit Life Span in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy: a Prospective Observational Study.

Optimized Calcium Supplementation Approach in Post-Dilution CVVHDF Using Regional Citrate Anticoagulation

Clinical Analysis of Continuous Venovenous Hemofiltration in Patients with Severe Congestive Heart Failure

Application of regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT) in patients with high risk of bleeding

Randomized Controlled Trial to Evaluate Regional Citrate Anticoagulation Plus Low-Dose of Dalteparin in Continuous Veno-Venous Hemofiltration

Safety and Feasibility of Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy With Calcium‐Containing Solutions: A Randomized Controlled Trial

Continuous Veno-Venous Hemofiltration in Treatment of Acute Severe Hyponatremia:A Report of 6 Cases

[Continuous veno-venous hemofiltration in treatment of acute severe hyponatremia: a report of 6 cases]

Calcium Supplementation in CVVH Using Regional Citrate Anticoagulation

Citrate Pharmacokinetics In Critically Illpatients With Acute Kidney Injury